source
- J&J advances IBD combo to Phase 3 despite Phase 2 setbacksJohnson & Johnson said it will advance its experimental inflammatory bowel disease therapy, JNJ-4804, into Phase 3 trials even though the drug failed to meet primary endpoints in two Phase 2 studie…
- Cytospire secures $83 million to develop pan-gamma delta T-cell engagersCytospire, a British biotechnology startup, announced it raised £61 million, about $83 million, to fund the development of a new type of T-cell engager therapy. The company is targeting a "pan-gam…